However, HNSCC is known to have low correlations between TMB and intratumoral T cell frequency (12), which can compromise the accuracy of predicting the anti-PD-1 therapeutic effect based on TMB. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.